Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Category: Health products
Remove filter for
Issue: Health products
Remove filter for
Last updated: 2022
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
- (-) 2022
- December 20228 results available
- November 20224 results available
- October 20229 results available
- September 20225 results available
- August 202213 results available
- July 20228 results available
- June 202210 results available
- May 20229 results available
- April 20228 results available
- March 202210 results available
- February 202210 results available
- January 20229 results available
Recall class
Displaying 91 - 103 of 103 items.
Alcohol Antiseptic 80% (v/v) Topical Solution Hand Sanitizer: Acetaldehyde outside acceptable limit
RecallHealth product recall | 2022-02-08
Auralgan: Impurities out of specification
RecallHealth product recall | 2022-02-04
Vitastack: missing risk statement
RecallHealth product recall | 2022-02-04
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03
Reddy-Dasatinib: out of specification
RecallHealth product recall | 2022-01-31
APO-AMITRIPTYLINE 10mg: NDMA impurity
RecallHealth product recall | 2022-01-26
ELAVIL 10mg: NDMA impurity
RecallHealth product recall | 2022-01-26
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
AlertHealth professional risk communication | 2022-01-17
Piperacillin and Tazobactam for injection: Particulate
RecallHealth product recall | 2022-01-17
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12
Shelf Life Extension for the SPIKEVAX (elasomeran) COVID-19 Vaccine with Printed Expiry Dates on Vial and Carton Labels
AlertHealth professional risk communication | 2022-01-11
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
AlertHealth professional risk communication | 2022-01-07